Business Context and Reporting Period
Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: A development-stage biopharmaceutical company focused on cancer therapies. The company operates as a result of a reverse acquisition completed in August 2008 between Sonus and OncoGenex Technologies. It has no product revenue and relies on financing to fund clinical trials for candidates including OGX-011 (prostate cancer), OGX-427, and others.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
Balance Sheet June 30, 2009 |
Balance Sheet Dec 31, 2008 |
|---|---|---|---|---|
| Revenue | $0 | $0 | - | - |
| Total Expenses | $7,067 | $3,201 | - | - |
| Net Loss | $(6,972) | $(3,825) | - | - |
| Cash & Cash Equivalents | - | - | $4,196 | $7,618 |
| Short-term Investments | - | - | $1,505 | $4,801 |
| Total Current Assets | - | - | $6,683 | $14,249 |
| Total Liabilities | - | - | $3,445 | $4,083 |
| Shareholders' Equity | - | - | $3,938 | $10,707 |
Loss Per Share (Basic & Diluted): $1.26 for the six months ended June 30, 2009 (compared to $45.29 in the prior year period, adjusted for share count changes due to the reverse takeover).
Material Changes vs. Prior Period
- Expense Increase: Total expenses rose to $7.1 million from $3.2 million year-over-year. Research and Development (R&D) expenses increased to $5.3 million from $2.0 million, driven by the purchase of the OGX-011 drug compound, payments to Bayer for the CSP-9222 license, and increased facility/employee costs following the reverse takeover of Sonus.
- Liquidity Decline: Cash, cash equivalents, and short-term investments decreased from $12.4 million at year-end 2008 to $5.7 million at June 30, 2009, due to operational burn.
- Restructuring Impact: A $494,000 expense was recorded in June 2009 due to a revision in the fair value estimate of the excess lease facility liability.
- Share Count: The weighted average shares outstanding increased significantly to ~5.55 million in 2009 from ~119,000 in 2008 due to the accounting treatment of the reverse acquisition.
Outlook, Risks, and Subsequent Events
- Capital Requirements: The company requires additional funding to support planned Phase 3 clinical trials for OGX-011. Management believes current cash resources will fund operations through 2010 but explicitly states that further financing is necessary for Phase 3 trials.
- Subsequent Event: On July 24, 2009, the company completed a registered direct offering of 475,000 shares at $20 per share, raising approximately $9.4 million in net proceeds.
- Clinical Progress: Phase 2 results for OGX-011 showed a survival benefit (23.8 months vs. 16.9 months) when combined with docetaxel. Phase 3 trial designs have been agreed upon with the FDA.
- Risks: Key risks include the inability to secure additional funding, uncertainty of clinical trial results, regulatory approval delays, and the potential inability to sublet excess office space in Bothell, Washington.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.7 million cash balance (plus the $9.4 million subsequent raise) against the projected costs of initiating Phase 3 trials for OGX-011.
- Lease Obligations: Review the $1.7 million liability for excess facilities and the company's progress in subletting the Bothell, WA office space to mitigate ongoing costs.
- Financing Terms: Confirm the terms of the July 2009 equity offering and any dilution effects on existing shareholders.
- Clinical Milestones: Monitor the initiation dates and enrollment progress of the two Phase 3 trials for OGX-011, as these are critical for future valuation.
- License Payments: Track upcoming milestone payments and annual fees due to Isis Pharmaceuticals and Bayer HealthCare.